Here's some of what is coming soon to NeurologyLive® this week.
News|Articles|September 28, 2026
This Week on NeurologyLive® — September 28, 2026
Author(s)Isabella Ciccone, MPH
Listen
0:00 / 0:00
Key Takeaways
- Several high-interest neurology topics are queued for publication during the week, framed as a focused preview of anticipated web coverage.
- Readers are prompted to review the broader site because additional reporting will accompany the highlighted themes.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Every week, the NeurologyLive® staff prepares this preview of what to expect from our coverage. This week on NeurologyLive, there are a number of hot topics that we will be posting on the website. As always, our weekly coverage extends beyond just these topics, so make sure to check out the rest of the site!
Click through the slides below to see what you can expect from our team this week. Click any slide to check out the content.
—————————————————
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Marketed as Fayuvi, the 1-time AAV9 gene therapy showed sustained cerebrospinal fluid heparan sulfate drops and developmental gains among pediatric patients with mucopolysaccharidosis type IIIA in prior studies.
Amy Waldman, MD, Medical Director of the Leukodystrophy Center at Children's Hospital of Philadelphia, discusses zilganersen's mechanism, safety profile, clinical considerations, and what the first-ever approval for Alexander disease means for the broader leukodystrophy field.
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Extends Relutrigine Review, Delays PDUFA to December
2
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
3
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
4
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
5